drugset
drugset / Trial / NCT04682210

Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection

NCT04682210 ↗

Phase 3 Unknown 246 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, multi-center, randomized, controlled phase III study, to evaluate the efficacy and safety of sintilimab plus bevacizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after radical resection

Timeline

Start
2020-12
Primary completion
2023-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

hepatocellular carcinoma